Caplin Point Laboratories Ltd Stock NSE India S.E.
Stocks
INE475E01018
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - INR | - |
|
| Market Cap | 197B 2.06B 1.8B 1.66B 1.54B 2.91B 2.96B 19.86B 7.8B 96.81B 7.74B 7.57B 333B | P/E 2026 |
17.9x | P/E 2027 * | 27.6x |
|---|---|---|---|---|---|
| Enterprise Value | 197B 2.06B 1.8B 1.66B 1.54B 2.91B 2.96B 19.86B 7.8B 96.81B 7.74B 7.57B 333B | EV / Sales 2026 |
5.23x | EV / Sales 2027 * | 7.9x |
| Free-Float |
26.39% | Yield 2026 * |
-
| Yield 2027 * | 0.15% |
Last Transcript: Caplin Point Laboratories Ltd
| Manager | Title | Age | Since |
|---|---|---|---|
Sridhar Ganesan
CEO | Chief Executive Officer | 71 | 2015-03-27 |
D. Muralidharan
DFI | Director of Finance/CFO | - | 2016-02-18 |
Anto V.
ADM | Chief Administrative Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 2010-01-26 | |
| Director/Board Member | - | 2025-11-04 | |
Sridhar Ganesan
BRD | Director/Board Member | 71 | 2015-03-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | +0.03% | +13.71% | +77.87% | 48.69B | |
| -1.65% | -5.82% | +66.16% | +114.68% | 36.38B | |
| -1.02% | -3.26% | -4.02% | +39.54% | 12.19B | |
| -0.92% | -0.61% | +17.81% | +92.90% | 12.04B | |
| +1.15% | +0.38% | +31.49% | +122.13% | 9.04B | |
| +0.75% | -0.82% | +18.53% | +38.49% | 7.09B | |
| -0.91% | -1.76% | +46.81% | -5.76% | 7.06B | |
| -0.49% | +0.04% | +2.37% | +232.51% | 6.75B | |
| +5.45% | -7.36% | -17.51% | +15.85% | 6.1B | |
| Average | +0.14% | -0.42% | +19.48% | +80.91% | 16.15B | |
| Weighted average by Cap. | -0.69% | +0.09% | +26.80% | +86.46% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 21.28B 223M 195M 180M 166M 315M 321M 2.15B 845M 10.48B 838M 819M 36.04B | 24.88B 261M 228M 210M 194M 369M 375M 2.51B 988M 12.26B 979M 958M 42.14B |
| Net income | 6.16B 64.61M 56.51M 52.13M 48.14M 91.35M 92.89M 623M 245M 3.04B 243M 237M 10.44B | 7.13B 74.73M 65.37M 60.29M 55.69M 106M 107M 720M 283M 3.51B 281M 274M 12.07B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
